- Home
- SKYE vs SRV Comparison
SKYE vs SRV Comparison
Compare SKYE & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SRV
- Stock Information
- Founded
- SKYE 2012
- SRV 2007
- Country
- SKYE United States
- SRV United States
- Employees
- SKYE N/A
- SRV N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- SKYE Health Care
- SRV Finance
- Exchange
- SKYE Nasdaq
- SRV Nasdaq
- Market Cap
- SKYE 108.3M
- SRV 123.3M
- IPO Year
- SKYE N/A
- SRV N/A
- Fundamental
- Price
- SKYE $2.46
- SRV $44.11
- Analyst Decision
- SKYE Buy
- SRV
- Analyst Count
- SKYE 6
- SRV 0
- Target Price
- SKYE $18.67
- SRV N/A
- AVG Volume (30 Days)
- SKYE 215.0K
- SRV 33.9K
- Earning Date
- SKYE 02-09-2025
- SRV 01-01-0001
- Dividend Yield
- SKYE N/A
- SRV 13.38%
- EPS Growth
- SKYE N/A
- SRV N/A
- EPS
- SKYE N/A
- SRV N/A
- Revenue
- SKYE N/A
- SRV N/A
- Revenue This Year
- SKYE N/A
- SRV N/A
- Revenue Next Year
- SKYE N/A
- SRV N/A
- P/E Ratio
- SKYE N/A
- SRV N/A
- Revenue Growth
- SKYE N/A
- SRV N/A
- 52 Week Low
- SKYE $2.25
- SRV $30.73
- 52 Week High
- SKYE $19.41
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- SKYE 25.13
- SRV 50.49
- Support Level
- SKYE $2.39
- SRV $40.10
- Resistance Level
- SKYE $3.55
- SRV $45.26
- Average True Range (ATR)
- SKYE 0.33
- SRV 1.08
- MACD
- SKYE -0.06
- SRV -0.00
- Stochastic Oscillator
- SKYE 4.59
- SRV 69.02
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.